Shuji Yoneyama, Director of the Osaka Research Center at Spera Pharma Co., Ltd. (Headquarters: Osaka City, Osaka Prefecture; President and CEO: Keitaro Iwaki), spoke at the seminar titled 'CMC Development ~Learning from Pioneers~' hosted by the nonprofit organizations LINK-J and DIA Japan on Wednesday, June 10, 2026.

At the seminar, Mr. Yoneyama delivered a presentation on the causes of rising costs and development delays in CMC development, along with strategies to avoid them. The event report, including details of the presentation, as well as the archived video, are now available on the official website of LINK-J.

▶ Event Report and Archived Video https://www.link-j.org/report/article-52950.html

Spera Pharma Co., Ltd. will continue to provide a wide range of services to support its clients in creating high-quality and innovative pharmaceutical products.

Company Overview: Spera Pharma Co., Ltd.

Company Name: Spera Pharma Co., Ltd. Headquarters: 2-17-85 Juso-Honmachi, Yodogawa-ku, Osaka City, Osaka Prefecture (Located within Takeda Pharmaceutical Company's Osaka Plant) Representative: President and CEO Keitaro Iwaki Founded: April 20, 2017 (Heisei 29) URL: https://www.spera-pharma.co.jp/ Business: Contract research, development, and manufacturing of pharmaceutical CMC

[Inquiries]

Spera Pharma Co., Ltd. Contact Form

https://www.spera-pharma.co.jp/inquiry/

FACT BOX

  • Source: PR TIMES
  • Category: Event
  • Organizations: LINK-J / DIA Japan